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Abstract
Background and Aims: In an attempt to further investigate the role of cannabinoid (CB) system in the pathogenesis of
inflammatory bowel diseases, we employed two recently developed ligands, AM841 (a covalently acting CB agonist) and
CB13 (a peripherally-restricted CB agonist) to establish whether central and peripheral CB sites are involved in the anti-
inflammatory action in the intestine.
Methods and Results: AM841 (0.01, 0.1 and 1 mg/kg, i.p.) significantly decreased inflammation scores in dextran sulfate
sodium (DSS)- and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-treated mice when administered before induction of colitis or
as a treatment of existing intestinal inflammation. The effect was absent in CB1, CB2 and CB1/2-deficient mice. A peripherally-
restricted agonist CB13 did not alleviate colitis when given i.p. (0.1 mg/kg), but significantly decreased inflammation score
after central administration (0.1 mg/animal).
Conclusions: This is the first evidence that central and peripheral CB receptors are responsible for the protective and
therapeutic action of cannabinoids in mouse models of colitis. Our observations provide new insight to CB pharmacology
and validate the use of novel ligands AM841 and CB13 as potent tools in CB-related research.
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Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) are two major
types of inflammatory bowel diseases (IBD). In clinical terms, UC
is limited to an inflammation of the mucosal lining of the colon
and rectum, while CD is a transmural inflammation of the
intestinal wall that can occur throughout the length of the
gastrointestinal (GI) tract (for review see: [1], [2]). The aetiology of
IBD remains unclear, but epidemiologic and molecular studies
suggest that genetic factors, a breakdown in mucosal defense,
environmental triggers (notably the luminal microbiota) and
altered immune responses within the GI tract converge to produce
chronic inflammation. Both UC and CD have elements of the
innate and acquired immune responses that underlie the
inflammation in the gut. In addition, there is an important
involvement of the nervous system in the pathophysiology of
colitis, including neuronal signalling in the enteric nervous system
(ENS) and extrinsic autonomic and primary afferent pathways
involving the central nervous system (CNS) [3–5]. One important
neural signaling system implicated in the pathophysiology of colitis
is the endogenous cannabinoid system (ECS).
The ECS consists of cannabinoid (CB) receptors, their
endogenous ligands, and the enzymes involved in endocannabi-
noid synthesis, transport and inactivation (for review see: [6]). To
date, two CB receptors, CB1 and CB2, have been identified in
mammalian tissues. The CB1 receptors are localized principally in
the CNS [7,8], but are also found in the peripheral tissues, like
ENS, small intestine, spleen and leukocytes [9–12]. The CB2
receptors are mainly distributed in immune cells, including B and
T lymphocytes, macrophages and neutrophils [10,13]. However,
the presence of CB2 in the ENS has also been detected [14]. The
endogenous ligands of CB receptors, N-arachidonoylethanolamine
(anandamide) and 2-arachidonoyl glycerol (2-AG) are found in the
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mammalian digestive tract, where they play an important role in
the regulation of GI motility, secretion, proliferation, and immune
functions (for review see: [6]).
Recently, it has been shown that CB receptor activation
prevents and ameliorates symptoms of inflammation in animal
models of experimental colitis [15–17] and the potential use of
therapeutics interacting with ECS has attracted attention as a
promising strategy for the treatment of IBD in humans. The
molecular mechanisms of the anti-inflammatory actions of
cannabinoids include CB1-promoted epithelial wound healing
[18], CB2-mediated inhibition of cytokine and chemokine release,
and immune cell recruitment [19,20], as well as CB-mediated
reduction of motility in inflamed intestine [21,22]. It was also
observed that the blockade of the CB1 receptors by antagonists or
genetic manipulations increased the severity of colitis [15]. The
increase of CB2 expression in the colonic epithelium of IBD
patients, which plays a key role in host defence, translated well the
key findings from animal tissues to humans [18,19].
A better understanding of mechanisms that protect against
inflammation is required for the development of novel, efficient
therapeutic strategies for the treatment of IBD. Although multiple
lines of evidence clearly indicate the anti-inflammatory effect of
cannabinoids on colitis, several questions remain unanswered. In
the present study we used two recently developed cannabinergic
ligands, a covalently acting CB agonist AM841 [23] and a
peripherally-restricted CB agonist CB13 [24] to determine
whether both, central and/or peripheral receptors mediate the
anti-inflammatory actions of cannabinoids. In addition, we wanted
to confirm whether cannabinoids have the potential to protect
against and to treat colitis at an advanced stage of its development.
To examine the anti-inflammatory actions of cannabinergic
ligands, we used two well-established animal models of colitis,








-/-) mice and their littermates on a C57Bl/6 background,
weighing 25–30 g, were used. Unless otherwise stated, experi-
ments were performed on CD1 mice (Charles River, Canada).
The animals were housed at a constant temperature (22uC) and
maintained under a 12-h light/dark cycle in sawdust-lined plastic
cages with free access to laboratory chow and tap water. The CB
knockout mice were bred in our facility at the University of
Calgary, Canada. All CB knockout mice were genotyped using an
established protocol [19] and confirmed as homozygous CB
receptor gene-deficient animals prior to inclusion in the study.
All animal protocols were approved by the University of
Calgary Animal Care Committee (protocol number M07102), and
the experiments were performed in accordance with the guidelines
of the Canadian Council on Animal Care.
Induction of colitis
DSS colitis. Colitis was induced by the addition of dextran
sulfate sodium (DSS) to drinking water (days 0–5; 4% wt/vol;
molecular weight, 36,000–50,000; MP Biomedicals, Aurora, OH,
USA, Lot No. 5237K) [25]. On days 6 and 7 the animals received
water without DSS.
TNBS colitis. Colitis was induced by intracolonic (i.c.)
administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS), as
described previously [25].
Pharmacological treatments
Drugs were administered intraperitoneally (i.p.) or centrally
(i.c.v.). AM841 (0.01–1 mg/kg, once or twice daily) and CB 13
(0.1 mg/kg, i.p. and 0.1 mg/animal, i.c.v., once daily) were
dissolved in vehicle (2% dimethyl sulfoxide and 1% Tween 80 in
saline) and injected 15 min before and then for 3 (TNBS model) or
7 days (DSS model) after the induction of colitis (n = 6–8 animals
per treatment group). Control animals received vehicle alone. To
investigate whether there is a beneficial effect of AM841 on
established colitis, the drug was injected once or twice daily from
day 4 following induction of DSS colitis. The doses of AM841 and
CB 13 were established based on preliminary experiments.
For the chemotactic assays, a stock solution of AM841 in
DMSO (1022 M) was prepared and diluted accordingly.
Evaluation of colonic damage
DSS colitis. Mice were sacrificed by cervical dislocation on day
7 following addition of DSS to the drinking water. The entire
colon was immediately dissected and weighed with fecal content.
Colon was then opened along the mesenteric border and fecal
material removed by gently rinsing with PBS. A total macroscopic
damage score was calculated for each animal as described
previously [25].
TNBS colitis. Animals were sacrificed by cervical dislocation 3
days after TNBS infusion. The colon was quickly removed,
opened longitudinally, washed with phosphate buffered saline
(PBS), and immediately examined. Macroscopic colonic damage
was assessed by an established semiquantitative scoring system by
adding individual scores for ulcer, colonic shortening, wall
thickness, and presence of hemorrhage, fecal blood, and diarrhea,
as described previously [25].
Determination of Tissue Myeloperoxidase Activity
Myeloperoxidase (MPO) activity was measured to assess the
degree of granulocyte infiltration. Colon segments (1 cm) were
weighed and processed immediately after isolation, according to
the method described previously [25]. MPO was expressed in
milliunits per gram of wet tissue, 1 unit being the quantity of
enzyme able to convert 1 mmol of hydrogen peroxide to water in
1 min at room temperature. Units of MPO activity per 1 min
were calculated from a standard curve using purified peroxidase
enzyme.
Histology
Following macroscopic scoring, segments of the distal colon
were stapled flat, mucosal side up, onto cardboard and fixed in
10% neutral-buffered formalin for 24 h at 4uC. Specimens were
then dehydrated, embedded in paraffin, sectioned at 5 mm and
mounted onto slides. Sections were stained with hematoxylin and
eosin and examined using a Zeiss Axioplan microscope (Carl Zeiss,
Toronto, ON, Canada). Photographs were taken using a digital
imaging system consisting of a digital camera (Sensys, Photo-
metrics, Tucson, AZ, USA) and image analysis software (V for
Windows, Digital, Optics, Auckland, New Zealand). A micro-
scopic total damage score was assessed as described previously
[25].
Isolation of bone marrow-derived neutrophils and
chemotactic assay
Neutrophils were isolated from untreated CD1 mice as
described previously [26]. They were pre-incubated for 30 min
with AM841 (0.1–10 nM) or RPMI alone to determine the
baseline migration. After pre-incubation, 0.2 ml of cell suspension
Central and Peripheral Cannabinoid Receptors in Colitis
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was transferred into the upper well of a 6.5 mm insert in 24-well
Transwell chemotaxis chamber (Corning Life Sciences, Lowell,
MA, USA) with an 8-mm polycarbonate membrane. Bottom wells
of the plate were filled with 0.6 ml of a 10 nM solution of the
synthetic neutrophil chemoattractant N-formyl-peptide (fMLP)
(Phoenix Pharmaceuticals, Burlingame, CA, USA). Plates were
incubated at 37uC in a humidified incubator for 3 h. Cells which
migrated to the lower chamber were counted in a hemocytometer.
Splenocyte cell isolation and differentiation into
macrophages
Spleens, isolated from untreated CD1 mice, were placed into
separate sterile Falcon tubes containing RPMI medium supple-
mented with 10% FBS (CanSera, Toronto, ON, Canada), 2%
penicillin/streptomycin and 25 mM 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid (HEPES) (both from Invitrogen Life
Technologies, Burlington, ON, Canada) and then mechanically
disrupted by pressing through a Falcon cell strainers (100 mm pore
size, BD Biosciences, Mississauga, ON, Canada). Cells were
centrifuged at 1400 rpm for 5 min and the pellets resuspended in
2 ml of ACK lysis buffer (150 mM NH4Cl, 10 mM KHCO3, and
0.1 mM EDTA) for 90 s to remove erythrocytes. Following
centrifugation, cells were resuspended in medium at 56106/ml for
immediate use.
For differentiation into a macrophage-like phenotype, splenic
cells were transferred into 24-well plates (1 ml/well), incubated for
2 h at 37uC under 5% CO2 and washed twice with PBS to remove
non-adherent cells. Cells were incubated with AM841 (1026 M) or
vehicle in medium for 1 h and then treated with LPS (5 mg/ml) for
24–48 h at 37uC. Cell viability was assessed using Trypan blue
staining method.
Phagocytosis assay
Phagocytic activity after AM841 exposure was evaluated in
colorimetric assay, as described previously [27]. Cells (56105 in
0.2 ml/well) were cultured on a 96-well plate and incubated for
30 min in cell medium containing neutral red stained zymosan
(0.26108 particles/well). Cells were fixed with 100 ml formol-
calcium solution (10% formalin, 2% sodium chloride, 1% calcium
acetate) for 30 min and washed twice with PBS. Cell-associated
stained zymosan was released by adding 0.1 ml of acidified alcohol
(10% acetic acid, 40% ethanol in distilled water) to each well and
incubation for 30 min at 37uC. Absorbance, measured at 550 nm
using microplate reader (Thermo Fischer Labsystems Multiskan,
Thermo Scientific, Ottawa, ON, Canada), was directly propor-
tional to the amount of ingested neutral red stained zymosan.
Neutral red uptake
The uptake of the cationic neutral red dye, which accumulates
in cell lysosomes, was used to assess the integrity of the
macrophage lysosomal system [28]. Cells (56105 in 0.2 ml/well)
were seeded on a 96-well plate, incubated for 30 min at 37uC with
20 ml of 3% neutral red in PBS and rinsed twice with PBS. Neutral
red was dissolved by 30 min incubation with 0.1 ml of 10% acetic
acid and 40% ethanol solution added to each well. Absorbance,
measured at 550 nm using microplate reader (Thermo Fischer
Labsystems Multiskan, Thermo Scientific, Ottawa, ON, Canada),
was directly proportional to the amount of neutral red.
Statistics
Statistical analysis was performed using Prism 4.0 (GraphPad
Software Inc., La Jolla, CA, USA). The data are expressed as
means 6 SEM. Student t-test or one-way ANOVA followed by
Newman-Keuls post-hoc test were used for analysis. P values ,
0.05 were considered statistically significant.
Drugs
All drugs and reagents, unless otherwise stated, were purchased
from Sigma-Aldrich (Oakville, ON, Canada). DSS (MW 40,000)
was purchased from MP Biomedicals (Solon, OH, USA). (2)-79-
isothiocyanato-11-hydroxy-19, 19-dimethylheptylhexahydrocanna-
binol (AM841) [29] was synthesized at the Center for Drug
Discovery, Northeastern University Boston, MA (AM, GT, RT).
1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone (CB 13)
was purchased from Tocris (Minneapolis, MN, USA).
Results
Cannabinoid receptor agonist AM841 protects against
DSS-induced colitis in mice
In order to evaluate the possible protective role of a CB receptor
agonist on intestinal inflammation, we examined animals treated
with DSS to induce colitis. Administration of DSS in drinking
water resulted in development of intestinal inflammation,
evidenced by a significant increase of macroscopic damage score
(Fig. 1A) and MPO activity (Fig. 1B), as compared with animals
receiving tap water. Treatment with the CB receptor agonist
AM841 (0.01, 0.1 and 1 mg/kg, i.p.) injected 15 min before and
once daily for 7 days following induction of colitis, significantly
attenuated colonic inflammation (Fig. 1). The effect of AM841 on
overall macroscopic damage score (7.5860.40, 5.1860.81, and
4.9060.81 for AM841 at the dose of 0.01, 0.1 and 1 mg/kg,
respectively vs. 7.5960.41 for DSS-treated mice) and the MPO
activity (44.468.5, 27.162.3, and 17.264.2 units for AM841 at
the dose of 0.01, 0.1 and 1 mg/kg, respectively vs. 47.665.4 units
for DSS-treated mice) was dose-dependent. However, the effect of
AM841 at the lowest (0.01 mg/kg) and the highest (1 mg/kg) dose
tested on colon weight and length, as well as stool score (data not
shown) was almost equipotent.
The microscopic evaluation of colon sections stained with
hematoxylin/eosin was in good agreement with the observation of
the macroscopic parameters. AM841 dose-dependently attenuated
inflammation by decreasing colonic tissue infiltration with
immunocytes, improving mucosal and muscular architecture,
and inhibiting ulceration (Fig. 1D). The microscopic damage
score was significantly decreased by AM841 at the two higher
doses tested (6.0060.52 and 4.6060.43 for 0.1 and 1 mg/kg, i.p.,
respectively vs. 8.8360.48 for DSS-treated mice, Fig. 1E).
A potent anti-inflammatory effect of the CB agonist was also
observed using a different type of dosing schedule. The i.p.
administration of AM841 (0.1 mg/kg, i.p.) injected 15 min before
and twice daily for 7 days following induction of colitis significantly
decreased macroscopic (5.0160.66 vs. 7.4060.50 for DSS-treated
mice) and microscopic colonic damage score (5.7860.32 vs.
8.5160.45 for DSS-treated mice). Interestingly, there was no
additional beneficial effect of AM841 on intestinal inflammation
associated with more frequent injections.
Anti-inflammatory effect of AM841 is absent in CB
receptor deficient mice




-/- mice. Since all CB receptor deficient mice
used in the study had a C57Bl/6 background, preliminary assays
were performed in order to establish the experimental conditions
and DSS treatment. Since no significant differences between the
parameters of inflammation were observed between DSS-treated
CD1 and C57Bl/6 wild type, or wild type and CB knockout mice,
Central and Peripheral Cannabinoid Receptors in Colitis
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therefore same DSS concentration and treatment schedule were
employed.
The i.p. administration of AM841 at the effective dose in wild
type animals (0.1 mg/kg, once daily) did not attenuate the DSS-
induced colitis in CB1
-/- (Fig. 2A), CB2
-/- (Fig. 2B) or CB1/2
-/-
mice (Fig. 2C). This lack of effect can be seen in the macroscopic
damage score and MPO activity (Fig. 2), as well as microscopic
colon damage score (data not shown).
Cannabinoid receptor agonist AM841 heals colitis in mice
Next we examined the effect of CB receptor activation on
intestinal inflammation in mice with clearly established colitis. At
the beginning of the experiment animals were treated with DSS in
drinking water and the development of intestinal colitis was
monitored based on clinical scoring (changes in body weight and
stool consistency, appearance of rectal bleeding). DSS-treated
animals with significantly increased clinical scores were randomly
Figure 1. Protective effect of AM841 (0.01, 0.1 and 1 mg/kg, i.p.) injected once daily for 7 days on DSS-induced colitis in mice. Figure
shows data for (A) macroscopic score, (B) MPO activity, (C) body weight, (D) representative micrographs for hematoxylin and eosin staining of colon
wall sections (i, control; ii, DSS; iii, DSS+AM841 0.01 mg/kg; iv, DSS+AM841 0.1 mg/kg; v, DSS+AM841 1 mg/kg; scale bar = 100 mm) and (E)
microscopic score. $$$p,0.001, as compared with control animals. *p,0.05, ***p,0.001, as compared with DSS-treated mice. Data represent means
6 SEM, n = 6–8.
doi:10.1371/journal.pone.0109115.g001
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assigned to groups receiving either vehicle or AM841 (0.1 mg/kg,
i.p.) once or twice daily on days 4–7 after induction of colitis.
Treatment with AM841 resulted in a significant attenuation of
intestinal inflammation and a decrease of total macroscopic
damage score (5.4060.92 and 3.6260.96 for AM841 injected
once and twice daily, respectively vs. 8.0960.43 for DSS-treated
mice, Fig. 3).
Cannabinoid receptor agonist AM841 protects against
TNBS-induced colitis in mice
To confirm the protective effect of the CB receptor agonist
AM841 against intestinal inflammation, the experiment was
performed in TNBS-treated mice (Fig. 4). Intracolonic adminis-
tration of vehicle (30% ethanol in saline) produced a minor
inflammation, which was significantly different from the TNBS-
induced colitis (macroscopic damage score 6.0760.21, microscop-
Figure 2. AM841 (0.1 mg/kg, i.p.) injected once daily for 7 days did not alter DSS-induced colitis in (A) CB1-/-, (B) CB2-/- (C) and CB1/
CB2-/- mice. Figure shows data for macroscopic score and MPO activity. $p,0.05, $$$p,0.001, as compared with control animals. Data represent
means 6 SEM, n = 6–8.
doi:10.1371/journal.pone.0109115.g002
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ic score 10.360.7, MPO activity 39.763.1 units in TNBS-treated
mice, n = 5–6). AM841 (0.1 mg/kg, i.p., once daily 15 min before
and for 3 days after induction of colitis) significantly attenuated
intestinal inflammation, as shown by a reduction of macroscopic
score (Fig. 4A) and MPO activity (Fig. 4B). No changes were seen
in and ulcer score (Fig. 4C) or body weight (Fig. 4D) after
treatment with AM841.
Effect of AM841 on neutrophil migration, cell viability
and phagocytic activity of splenocyte-derived
macrophages
In order to characterize the molecular mechanism of anti-
inflammatory action of AM841, we performed a chemotactic assay
with neutrophils isolated from mouse bone marrow, using fMLP as
chemoattractant. AM841 (0.1–10 nM) inhibited fMLP-stimulated
neutrophil migration in a concentration-dependent manner
(Fig. 5). The CB receptor agonist alone had no effect on
spontaneous neutrophil migration.
To further investigate the possible action of AM841 in inflamed
colonic tissues, macrophage-like cells were obtained from spleno-
cytes isolated from control and DSS- or TNBS-treated mice.
Incubation of macrophages isolated from control and DSS-treated
animals with AM841 (10-6 M) for 48 h did not influence their
viability as measured using a Trypan blue staining method
(AM841 decreased the number of viable cells by 5.3262.62 and
9.7864.51% in control and DSS-treated animals, respectively).
However, the number of cells obtained from mice with TNBS-
induced colitis was significantly reduced by 52.9466.97% after
incubation with AM841.
AM841 (1026 M) decreased phagocytic activity by 10.4664.65
and 15.465.43% in DSS- and TNBS-treated animals, respective-
ly. Neutral red uptake, which indicates the integrity of the
macrophage lysosomal system, was inhibited by 15.3867.37 and
14.2869.46% in DSS- and TNBS-treated animals, respectively.
Activation of peripheral cannabinoid receptors protects
against DSS-induced colitis in mice
In an attempt to elucidate the role of peripheral CB receptors in
the anti-inflammatory activity of cannabinoid agonists, the effect
of a peripherally-restricted agonist CB 13 on TNBS-induced colitis
was evaluated (Fig. 6). The i.p. administration of CB 13 (0.1 mg/
kg) once daily 15 min before and for 3 days after induction of
colitis did not influence the macroscopic damage score (Fig. 6A),
MPO activity (Fig. 6B) or ulcer score (Fig. 6C). However, the
Figure 3. Therapeutic effect of AM841 (0.1 mg/kg, i.p.) injected once or twice daily from day 4 on DSS-induced colitis in mice. Figure
shows data for (A) macroscopic score, (B) MPO activity and (C) body weight. $$p,0.01, $$$p,0.001, as compared with control animals. *p,0.05,
**p,0.01, as compared with DSS-treated mice. Data represent means 6 SEM, n = 6–8.
doi:10.1371/journal.pone.0109115.g003
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peripherally-restricted CB agonist significantly attenuated macro-
scopic and ulcer scores (Fig. 6A and C, respectively) when injected
centrally at the dose of 0.1 mg/animal.
Discussion
The involvement of the ECS in the development of intestinal
inflammation in animal models and human colitis has recently
been suggested [17,19]. The aim of the present study was to gain a
deeper insight into the pharmacology of cannabinoids in colitis
using high-affinity probes at CB receptors, and to see if the effects
of CB receptor activation are centrally and/or peripherally-
restricted. We observed a beneficial effect of CB receptor
activation such that colitis was prevented or healed following
treatment with AM841. We also showed that the presence of CB1
or CB2 receptors is sufficient to confer the anti-inflammatory
effects of cannabinoids in these experimental models of colitis.
Finally, we demonstrated that for full protection, central and
peripheral CB receptors are required.
AM841 is a novel cannabinergic ligand that was designed to
interact with specific amino acid residues at or immediately
adjacent to the CB1 and/or CB2 receptor-binding pocket [23,30].
AM841 has been very effective in selective binding to CB1
receptors in rat brain synaptosomes [23] and hCB2 in transfected
HEK293 cell line [30]. The remarkable specificity and potency at
CB receptors make AM841 as useful tool in studying the
involvement of cannabinoids in physiological processes, both in
vitro and in vivo. In addition, unlike many cannabinoids including
the endogenous CB ligand anandamide, AM841 does not activate
non-CB receptor targets, such as the vanilloid receptor TRPV1
[31]. CB 13 on the other hand is a recently developed, potent
orally bioavailable human CB1/CB2 dual agonist.
In our study, AM841, but not CB 13 was effective after
peripheral administration, suggesting that a central component is
important in the anti-inflammatory actions of CB agonists. These
data are consistent with the observations made by Cluny et al.,
who showed that the peripherally restricted CB agonist SAB378
was ineffective at reducing colitis [32]. The most striking
observation here was that the anti-inflammatory effect of CB 13
Figure 4. Protective effect of AM841 (0.1 mg/kg, i.p.) injected once daily for 3 days on TNBS-induced colitis in mice. Figure shows
data for (A) macroscopic score, (B) MPO activity, (C) ulcer score and (D) body weight. $$$p,0.001, as compared with control animals. **p,0.01,
***p,0.001, as compared with TNBS-treated mice. Data represent means 6 SEM, n = 6–8.
doi:10.1371/journal.pone.0109115.g004
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was revealed after central administration, as demonstrated by a
significant decrease of macroscopic damage and ulcer score. The
activation of centrally located CB receptors seems thus crucial for
the anti-inflammatory action of cannabinoids and this observation
may have a tremendous impact on further development of this
class of compounds for potential clinical application in colonic
inflammation treatment.
An important contribution to our understanding of the CB
receptor pharmacology is the absence of an anti-inflammatory
effect of AM841 in CB1
-/-, CB2
-/- and CB1/2
-/- mice. Contrary to
what we expected AM841, a CB agonist with a considerable
preference to CB1 over CB2 receptors, did not attenuate colitis in
animals lacking the CB2 receptor, which confirms our earlier
observations [19]. Our results indicate that the expression of both
CB receptors is required for the ECS to protect against colitis and
that the drugs non-selectively targeting CB1 and CB2 could be
more efficient anti-inflammatory therapeutics. Further studies are
thus required to explain this phenomenon.
The protective effect of cannabinoids on colitis and the
involvement of the CB receptors in mediation of their anti-
inflammatory effects have been demonstrated [15–19]. In our
study, as expected, both CB agonists produced a significant
protective effect on DSS- and TNBS-induced colitis. A key finding
of our study is, in addition to well-documented protective effects,
the ability of CB receptor agonists to heal the intestinal
inflammation at an advanced stage. Previously published data
indicated a possible protective effect of cannabinoids in mustard
oil -induced colitis, which is regarded as a model for neurogenic
colonic inflammation [16]. Kimball et al. [16] showed that the
CB1 receptor agonist attenuated mustard oil-colitis by prophylactic
and therapeutic dosing regimen, whereas the CB2 agonist was
more effective in late administration. These results, along with our
observations, imply the crucial role of ECS in the development of
colitis and suggest a potential application of CB receptor agonists
in the treatment of colonic inflammation even at later time points.
Interestingly, MPO activity, which is an indicator of neutrophil
infiltration, but not macroscopic or microscopic scores were
affected by a dosing schedule of AM841 applied in a therapeutic
manner in DSS-treated mice. This observation suggests that the
activation of the immune system is crucial for therapeutic effects of
cannabinoids and suggested that the CB2 receptors, which are
predominantly expressed on neutrophils, may be important
mediators of their anti-inflammatory action.
The influence of AM841 on migratory properties of neutrophils
in vivo was subsequently investigated and confirmed in the
chemotactic assay in vitro. AM841 concentration-dependently
inhibited chemoattractant-stimulated migration of neutrophils.
This observation, which is in line with previous reports showing
the ability of anandamide, 2-AG and synthetic cannabinoids to
inhibit neutrophil migration in response to fMLP [33] and other
chemoattractants [34,35] bears great therapeutic potential.
Infiltration of leukocytes, primarily neutrophils, and their inap-
propriate activation can cause local inflammation and increase the
release of pro-inflammatory cytokines, leading to a number of
autoimmune, inflammatory, and neoplastic disorders (for review
see: [36]). Inhibition of neutrophil chemotactic activity might thus
be an important feature of the anti-inflammatory action of
cannabinoids in colitis. However, although the presence of the CB
receptors on neutrophils was described [10,13], it was also
suggested that the action of cannabinoids could be mediated by
CB1/CB2-independent mechanisms [33]. Therefore further stud-
ies are required to elucidate the role of CB receptors in neutrophil-
related effects.
Studies in vitro have shown that cannabinoids reduced
proliferative responses of mouse splenic T and B cells [37–39],
cytotoxic T cell activity [40], and antibody synthesis [41]. In an
attempt to further characterize the molecular mechanisms
underlying the anti-inflammatory action of cannabinoids, we
examined the effect of AM841 on proliferative response of
splenocyte-derived macrophages. Macrophages are an important
element of immune defence systems, as they engulf and destroy the
antigens upon activation of innate immunity, as well as present
processed antigens to immunologically naive lymphocytes in an
early recognition phase of acquired immunity [42] and were thus
examined in our study. The expression of CB1 and CB2 receptors
on macrophages has also been demonstrated [18,43]. Interesting-
ly, the CB receptor agonist AM841did not affect the proliferation
of macrophages obtained from DSS-treated mice, but significantly
decreased the viability of cells from the TNBS-treated animals.
Furthermore, the incubation of splenocyte-derived macrophages
with AM841 did not affect their phagocytic activity. This is in
good agreement with a study by Mann et al. [44], who observed
that the exposure to marijuana smoke did not alter the phagocytic
capacity, but caused metabolic and morphological changes in
alveolar macrophages from humans and rats, but contradicts other
studies showing that macrophage spreading, phagocytosis and cell
metabolism may be modulated through CB receptor-dependent
mechanisms [45–48]. The clinical relevance of our findings
remains unclear, but suggests the immunomodulatory potential
of macrophages, which may become a future target for
cannabinoids in the treatment of intestinal inflammation.
Conclusion
In conclusion, in the present study we showed that the CB
receptor agonists AM841 and CB 13 displayed protective and
therapeutic effects on colitis in mice. Most importantly, we
demonstrated that the anti-inflammatory action of the cannabi-
noids was mediated through CB1 and CB2 receptors localized
centrally and possibly to a lesser extent - peripherally. To the best
of our knowledge, this is the first evidence showing the
involvement of central CB receptors in development and
treatment of colitis. These results are crucial for our understanding
of the pharmacology of CB ligands in GI inflammation and may
Figure 5. Chemotactic assay with murine neutrophils. AM841
(0.1–100 nM) inhibited neutrophil migration to 10 nM fMLP in a
concentration-dependent manner. $p,0.05, $$$p,0.001, as compared
with vehicle-treated controls. Data represent means 6 SEM of 4
independent experiments performed in duplicate.
doi:10.1371/journal.pone.0109115.g005
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have potential applications in the development of future treatment
strategies for IBD in humans.
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